AstraZeneca · 3 days ago
Executive Director, Business Development, RDU
US - Boston - MA
Full-time
Onsite
Director/Executive
8+ years expAstraZeneca, through its Alexion Pharmaceuticals division, is a leader in the BioPharmaceutical landscape focused on innovative medicines for rare diseases. The Executive Director of Business Development will be responsible for leading sophisticated transactions, mentoring team members, and ensuring the acceleration of innovative medicines to patients globally.
BiopharmaBiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
Responsibilities
Identifying opportunities by: reviewing scientific and industry publications; networking, attending medical/scientific meetings, banking, and partnering conferences; and maintaining relationships with world-class investors and VCs
Ensuring efficient triaging and evaluation of new opportunities leading to recommendations and prioritization of only the highest quality opportunities
Ensuring priority BD opportunities are progressed efficiently to appropriate conclusion or deal execution, including: structuring deal terms around key risks/ value inflections; business case development; financial modeling; and contract negotiations
Leading cross-functional teams through meticulous, but right-sized evaluation and due diligence, including: Clinical, Research, Commercial, Regulatory, Finance, Legal, and Manufacturing
Driving well-informed decision making with “executive-ready” deliverables presented at appropriate governance forums
Giving to and adjusting the overall BD strategy to meet corporate objectives
Collaborate and engage with colleagues in broader AstraZeneca teams, as appropriate for the deal type and stage, including AstraZeneca Oncology, AstraZeneca Biopharmaceuticals, BDO, Corporate Development, Corporate Ventures, and Deal Finance
Engage anticipated post-close partners (*e.g.,* Alliance and Integration Management, R&D or business owners) at the appropriate time to ensure input into deal structure and terms, effective project initiation and transition, and communication of risks/ mitigations
Mentor peer colleagues with guidance and innovative methodologies
Qualification
Required
Minimum eight years of experience in pharmaceutical/ biotech BD, with proven track record structuring terms, due diligence, negotiations, and closing transactions
Master's or Post-graduate degree in business (e.g., MBA) or scientific field (e.g., PhD, MD)
Proven track record practicing good judgment in risk identification, assessment, and translation to well-structured deal terms
Experience interacting with and facilitating decisions on BD matters with senior management
Deep understanding of or direct experience in the different functions within a global biotech company and steps needed for successful development and commercialization of biotech or pharmaceutical products
Ability to work collaboratively with cross-functional teams, build intra-team relationships, and collaborate in a global team environment at all levels of the organization
Strong analytical, communication, and project and process management skills
Ability to draft and present clear, succinct, and convincing presentations at varying levels of detail depending on the project scope
Ability to work in a fast-paced environment and manage complex issues, problem solve, and coordinate multiple projects simultaneously
Sense of ethics and responsibility
Ability to travel as business needs require
Preferred
Broad knowledge of, experience, and network in rare disease space (strongly preferred)
Experience in drug development for orphan indications
Experience using artificial intelligence tools to accelerate BD evaluations, screening for assets, or other relevant applications
Multi-region experience – US, EU, Japan, China, Emerging Markets
Comfort with principles of corporate finance and accounting relevant to structuring deal terms and familiarity with financial models
Company
AstraZeneca
AstraZeneca is a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. It is a sub-organization of Investor.
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$5.26B2024-07-30Post Ipo Debt· $1.51B
2023-02-28Post Ipo Debt· $2.25B
2023-02-24Post Ipo Debt· $1.5B
Leadership Team
Pascal Soriot
Chief Executive Officer
Aradhana Sarin
Group CFO and Executive Director
Recent News
2026-01-23
Pharma Letter
2026-01-22
Company data provided by crunchbase